Macrophage activation syndrome and cytokine-directed therapies.
about
Safety of tocilizumab in the treatment of juvenile idiopathic arthritis.F4/80+ Host Macrophages Are a Barrier to Murine Embryonic Stem Cell-Derived Hematopoietic Progenitor Engraftment In Vivo.Macrophage Activation Syndrome.Refractory adult-onset Still disease complicated by macrophage activation syndrome and acute myocarditis: A case report treated with high doses (8 mg/kg/d) of anakinra11-Month-Old Infant With Periodic Fevers, Recurrent Liver Dysfunction, and Perforin Gene Polymorphism.Successful Treatment with Intravenous Cyclophosphamide for Refractory Adult-Onset Still's Disease.A xenograft model of macrophage activation syndrome amenable to anti-CD33 and anti-IL-6R treatment.Macrophage Activation Syndrome as Onset of Systemic Lupus Erythematosus: A Case Report and a Review of the Literature.Clinical features and correct diagnosis of macrophage activation syndrome.Tocilizumab for treating juvenile idiopathic arthritis.An atypical presentation of adult-onset Still's disease complicated by pulmonary hypertension and macrophage activation syndrome treated with immunosuppression: a case-based review of the literature.Kv1.3 channel blockade enhances the phagocytic function of RAW264.7 macrophages.Antimalarial myopathy in a systemic lupus erythematosus patient with quadriparesis and seizures: a case-based review.New frontiers in the treatment of systemic juvenile idiopathic arthritis.Macrophage Activation Syndrome Associated with Adult-Onset Still's Disease Successfully Treated with Anakinra.The clinical utility of splenic fluorodeoxyglucose uptake for diagnosis and prognosis in patients with macrophage activation syndrome.Rate and Clinical Presentation of Macrophage Activation Syndrome in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Canakinumab.Broadleaf Mahonia attenuates granulomatous lobular mastitis‑associated inflammation by inhibiting CCL‑5 expression in macrophages.Macrophage Activation Syndrome: A Report of Two Cases and a Literature Review.The role of the interleukin-1 family in trained immunity.Anaphylaxis in the 21st century: phenotypes, endotypes, and biomarkers.Adult-Onset Still's Disease and Macrophage-Activating Syndrome Progressing to Lymphoma: A Clinical Pathology Conference Held by the Division of Rheumatology at Hospital for Special SurgeryMacrophage Activation Syndrome, Glomerulonephritis, Pericarditis, and Retinal Vasculitis as Initial Presentation of Systemic Lupus Erythematosus
P2860
Q30235357-F5AE323C-63DE-44D1-9F7F-7192EF709512Q30828462-3A7DE7AC-2A67-4743-A73C-7786EF62948AQ33426151-C42F9D71-93E4-4BFD-85A9-A7CB3B9E2861Q33817997-2E5D464D-BA9C-4D74-9AFB-8210CC5277C0Q35674985-C90EC389-2AD6-419D-96E8-0669E015A574Q36427179-4387E27C-AC6C-4F55-8EEA-DA2EB8439AECQ37277020-01E6B904-2195-45D1-A08D-12C683AFC34FQ38524639-5A62798A-D44A-4DF8-BD44-37FFD628711BQ38530013-3AE9150C-BB40-4E21-953C-4378F4432FE4Q38723988-1AD3CBB5-39CC-4517-AF3C-B49EC86A0104Q38830731-E537F8AA-C43F-432C-8940-73FCF0584B0AQ38836515-973D0DEE-1B5A-44B4-83CB-2C5C974F432FQ39150067-CF6F8445-D9C4-4712-9F3D-1066A3CA793CQ39424746-46CA22EC-66F4-47D4-879E-4D8A86F1E6D9Q40081000-5FED793D-4964-48FB-952F-FC0F5D15D8B1Q40082328-F9EBD8AB-53A7-4513-AF82-E336E01EBBF4Q41029387-89C83763-3C66-4187-852D-86B777F776CDQ46261261-6B89D068-5602-4294-B110-056666CDB2E1Q46462480-11D1DAC7-32E5-4F73-8BF0-1D67A33FE118Q48105533-03519295-B533-4425-8A39-A0DE06D29A12Q55374006-53B30F06-AC4E-4362-916B-02B25DDBDD91Q56529255-6CD7C096-4C8C-45AD-8785-4D8E023EA3E8Q57821249-A7A1CA3F-9E0F-4A1E-9458-A19F9A771444
P2860
Macrophage activation syndrome and cytokine-directed therapies.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Macrophage activation syndrome and cytokine-directed therapies.
@en
type
label
Macrophage activation syndrome and cytokine-directed therapies.
@en
prefLabel
Macrophage activation syndrome and cytokine-directed therapies.
@en
P2860
P1476
Macrophage activation syndrome and cytokine-directed therapies.
@en
P2093
Alexei A Grom
Grant S Schulert
P2860
P304
P356
10.1016/J.BERH.2014.03.002
P577
2014-04-01T00:00:00Z